Zoledronic acid use in cancer patients
Authors:
Open Access
Abstract
Bone is the most common site for metastasis from solid tumors, and the majority of patients will develop bone metastases during the natural course of their disease. Bisphosphonates are an effective treatment for preventing skeletal‐related events in patients with bone metastases and may preserve functional independence and quality of life. Although several bisphosphonates have been investigated in patients with solid tumors, only zoledronic acid (ZOL) is approved by the US Food and Drug Administration and the European Medicines Agency for preventing skeletal‐related events in patients across a broad range of solid tumors. In addition, bisphosphonates, notably ZOL, prevent cancer treatment‐induced bone loss in breast and prostate cancer patients who are receiving endocrine therapy. It also has been demonstrated that ZOL directly and indirectly inhibits cancer cell growth in vitro and growth and tumorigenesis in animal model systems. These properties may produce clinically meaningful benefits. In recent clinical studies in patients with cancer, ZOL improved overall and prolonged disease‐free survival. Ongoing clinical trials in patients with solid tumors will provide further insight into the potential of ZOL to prevent distant metastases and improve survival. Cancer 2011. © 2010 American Cancer Society.Keywords
This publication has 75 references indexed in Scilit:
- Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trialsThe Lancet Oncology, 2009
- Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast CancerNew England Journal of Medicine, 2009
- Antitumor Effects of Doxorubicin Followed by Zoledronic Acid in a Mouse Model of Breast CancerJNCI: Journal of the National Cancer Institute, 2008
- Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acidCancer, 2008
- Practical guidance for the management of aromatase inhibitor-associated bone lossAnnals of Oncology, 2008
- Zoledronic Acid and Survival in Patients with Metastatic Bone Disease from Lung Cancer and Elevated Markers of Osteoclast ActivityJournal of Thoracic Oncology, 2008
- Effect of zoledronic acid on the doxycycline-induced decrease in tumour burden in a bone metastasis model of human breast cancerBritish Journal of Cancer, 2007
- Variation in the use of chemotherapy in lung cancerBritish Journal of Cancer, 2007
- Meta-analysis of clodronate and breast cancer survivalBritish Journal of Cancer, 2007
- Dissemination and growth of cancer cells in metastatic sitesNature Reviews Cancer, 2002